For the quarter ending 2025-09-30, TSHA had -$15,417K decrease in cash & cash equivalents over the period. -$24,274K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -32,733 | -48,411 |
| Depreciation expense | 286 | 560 |
| Stock-based compensation | 3,285 | 6,484 |
| Change in fair value of warrant liability | 292 | 171 |
| Non-cash change in fair value of term loan | 186 | 441 |
| Debt issuance costs expensed under the fair value option | 147 | - |
| Non-cash lease expense | 312 | 647 |
| Other | -28 | -236 |
| Prepaid expenses and other assets | -971 | 570 |
| Accounts payable | -1,948 | 3,921 |
| Accrued expenses and other liabilities | 5,008 | -1,393 |
| Deferred revenue | 0 | -4,288 |
| Net cash used in operating activities | -24,166 | -42,202 |
| Purchase of property, plant and equipment | 108 | 380 |
| Other | -60 | -71 |
| Net cash used in investing activities | -48 | -309 |
| Proceeds from issuance of common stock and pre-funded warrants from underwritten public offering, net of underwriting discounts and sales commissions and other offering costs | -454 | 216,170 |
| Prepayment of 2023 trinity term loan | 40,612 | - |
| Proceeds from 2025 trinity term loan, net | 49,853 | - |
| Payment of shelf registration costs | -14 | 47 |
| Proceeds from common stock issuances under espp | 84 | 75 |
| Proceeds from stock option exercises | 197 | - |
| Other | -285 | 38 |
| Net cash provided by financing activities | 8,797 | 216,236 |
| Net increase in cash, cash equivalents and restricted cash | -15,417 | 173,725 |
| Cash and cash equivalents at beginning of period | 141,636 | - |
| Cash and cash equivalents at end of period | 299,944 | - |
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)